Prime Therapeutics' leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years

Prime Therapeutics' leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years

Findings also show improved persistence with high-potency, obesity-approved GLP-1 products

Only one in 12 remain on a GLP-1 drug for obesity at three years

Only 8% of individuals (or one in 12) initiating a glucagon-like peptide-1 (GLP-1) agonist drug for obesity without diabetes continued to do so at three years, according to the latest real-world research from Prime Therapeutics (Prime). Meanwhile, individuals who took a high-potency GLP-1 drug approved for obesity - such as semaglutide - had greater persistence at 14% three years after initiating therapy.While overall persistence continues to de…

GLP-1s Serving as the Intersection of Cost, Utilization

Pharmaceutical Strategies Group experts joined Drug Topics to discuss the role GLP-1s play in drug benefit design.

New data show most US patients now stay on Wegovy, Zepbound after a year

A recent analysis of U.S. pharmacy claims reveals that nearly two-thirds of patients who initiated Wegovy or Zepbound in early 2024 continued their treatment a year later. This marks a significant increase in persistence compared to previous years, potentially driven by improved drug availability, expanded insurance coverage, and enhanced management of side effects by healthcare professionals.